Kag...like I said, that is a possibility but I'm not sure about the economics. Meaning...why would Abbott simply replace PSA revenue with RECAF revenue? Makes no sense to me. Now, if Abbott were to use a combined PSA & RECAF test, they would get double the revenue rather than simply replacing existing revenue.
Believe it or not, big pharma designs their trials and prepares their BLA/PMA/510k/etc apps so that they can bring the product to market in the most profitable manner. I don't see why they would design a PSA vs RECAF trial...too much at stake for them. They are pitting themselves against themselves (not that ABT holds an exclusive to PSA, but you get the point).
I would love to see us partner, rather than compete with, the existing cancer tests. It seems ABT would prefer that, too. But who knows...it's all conjecture and we've discussed this stuff ad nauseum. Looking forward to some guidance from the company...
Take care,
BOCXMAN
News 
Market Data 
Discover 
